Novo Nordisk(US:NVO) Ge Long Hui·2026-01-09 09:20Group 1 - The core viewpoint of the news is that Novo Nordisk (NVO.US) continues to show strong performance, with a pre-market increase of over 2% following a five-day consecutive rise, supported by a "outperform" rating from CICC and a target price of $73.50 [1] - Novo Nordisk is recognized as a leader in the global metabolic disease market, with the growth of the GLP-1 market driven by semaglutide, projected to have a CAGR of 23% from 2024 to 2030 [1] - The company has a robust pipeline that supports future competition, with CagriSema and Amycretin expected to launch in 2027/28, contributing to a "dual leadership" market position [1] - Novo Nordisk is strategically transforming into a comprehensive chronic disease platform, which is expected to enhance its valuation premium [1] Group 2 - As of January 8, the closing price of Novo Nordisk was $57.34, with a pre-market price of $58.59, reflecting a 2.18% increase [2] - The stock has a total market capitalization of $254.63 billion, with a P/E ratio of 16.24 and a P/B ratio of 9.607 [2] - The stock's 52-week high is $91.225 and the low is $43.080, indicating significant price volatility over the past year [2]